Estrogen therapy in patients with prostate cancer: a contemporary systematic review

摘要: To evaluate the effectiveness and harms of DES in treating prostate cancer compared to other forms androgen deprivation therapy (orchiectomy, LHRH agonists, anti-androgens). We included clinical trials comparing with ADT (bicalutamide, flutamide, or orchiectomy) PCa treatment. The primary outcomes were overall survival, cancer-specific progression-free secondary cardiovascular effects. We searched MEDLINE, EMBASE, Central, Lilacs from inception nowadays saturated information for unpublished data sources. performed a qualitative analysis all studies. It was not possible perform meta-analysis due low-quality high heterogeneity. Overall, 1700 references scanned 14 prospective randomized total 3986 patients final analysis. Although showed as similarly effective another ADT, evidences about toxicity out date doses have discouraged its use. In 1 mg, has been used line treatment safety. might be on advanced patients, potential important roles. Intriguingly, burden severe is mainly related old-fashioned 5.0 3.0 mg. Modern hormonal knowledge warrants stout high-quality low-dose 1 mg scenario.